This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montgomery, J. A. Search for Related Content PubMed PubMed Citation Articles by Montgomery, J. A.

Has the Well Gone Dry? The First Cain Memorial Award Lecture¹

Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama 35255

Contrary to a recent suggestion, new and useful drugs for the treatment of human cancer continue to be developed although clinical trials today are more difficult and the chances for success are diminished. In the past, research at Southern Research Institute led to the development of two new classes of clinically useful anticancer agents, the nitrosoureas and the imidazole triazines. More recently, we have developed an interesting family of cytotoxic compounds, the haloadenine nucleosides, thar are resistant to deamination and show biological activity comparable to the corresponding adenine nucleosides given in combination with 2'-deoxycoformycin, a potent inhibitor of adenosine deaminase. Among them, the 2-haloadenine arabinonucleosides and 2'-deoxyribonucleosides appear to have the necessary selectivity for neoplastic cells to be useful anticancer agents.

¹ Most of the work described in this lecture was supported by the Division of Cancer Treatment, National Cancer Institute, Department of Health and Human Services, Contract NO1-CM-43756, NO1-43762, and NO1-43784 and Grants CA-23155, CA-27448, and CA-42975. Presented April 28, 1982 at the Seventy-Third Annual Meeting of the American Association for Cancer Research, St. Louis, Mo.

This article has been cited by other articles:

				J. M. Kolesar, A. K. Morris, and J. G. Kuhn Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181. [Abstract] [PDF]